What to expect from targeted radioisotope therapy for neuroblastoma

The therapy uses a radioactive substance attached to a carrier that can seek a target found on some neuroblastoma cells. Before treatment, the team reviews scans, blood tests, kidney function, medicines and overall health. Protective medicines or fluids may be used, and a central line may make treatment easier.

The radioactive medicine is usually given through a vein in a specialised setting. Some of the radiation leaves the body through urine and other body fluids, so the team measures radiation levels and explains how long precautions are needed. Possible effects include nausea, tiredness, changes in blood counts and irritation around the treatment line.

Tell the team about all medicines, allergies, pregnancy concerns and recent illness. Follow instructions about drinking fluids, using the toilet, hand hygiene and contact with household members. Keep the care team’s number available, take anti-sickness medicine as directed, and attend blood-test appointments. Do not change medicines or miss follow-up without discussing it.

Call promptly for fever, chills, repeated vomiting, inability to drink, reduced urine, unusual bruising or bleeding, or worsening pain and swelling at the line site. Seek urgent help for trouble breathing, collapse, severe allergic symptoms or uncontrolled bleeding. Radiation precautions are personalised, so follow the written instructions from the treating unit.

Ask what target the medicine recognises, why it is suitable, how many visits are planned, whether admission is needed, which side effects require a call, and when blood counts and scans will be reviewed. Ask how to manage contact with children, pregnant people and pets during the safety period.